Stockhub

Regemat 3D: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

20 August 2022

22 July 2022

17 May 2022

26 April 2022

  • curprev 22:0022:00, 26 April 2022‎ Susan talk contribs‎ 3,627 bytes +3,627‎ Created page with "==Summary== Regemat3D develops bioprinters and bioreactors that allow researchers to print cartilage, meniscus, muscle tissue and spinal cord, with the ultimate aim of improving patients quality of life. 2021 Revenue reached: €890k and EBITDA €11k (Revenue CAGR 2016-21 grew by +36%) * Global bioprinting market is estimated to be worth approx $1.6bn by 2024. * Technology based in bioprinters and bioreactors * Collaboration project with Rovi Pharmaceutics (Market Ca..." Tag: Visual edit: Switched
Retrieved from ‘https://stockhub.co/research/Regemat_3D’